



GOLD Combined COPD Assessment & Management

Refined ABCD Assessment Tool




Treatment of Stable COPD Initial Pharmacologic Treatment



GOLD Combined COPD Assessment & Management

Follow-up Pharmacologic Treatment

1. IF RESPONSE TO INITIAL TREATMENT IS APPROPRIATE, MAINTAIN IT.
2. IF NOT:
 - ✓ Consider the predominant treatable trait to target (dyspnea or exacerbations)
 - Use exacerbation pathway if both exacerbations and dyspnea need to be targeted
 - ✓ Place patient in box corresponding to current treatment & follow indications
 - ✓ Assess response, adjust and review
 - ✓ These recommendations do not depend on the ABCD assessment at diagnosis



eos = blood eosinophil count (cells/ μ L)

** Consider if eos \geq 300 or eos \geq 100 AND \geq 2 moderate exacerbations / 1 hospitalization*

*** Consider de-escalation of ICS or switch if pneumonia, inappropriate original indication or lack of response to ICS*

Abbreviations

CAT = COPD Assessment Test; COPD = chronic obstructive pulmonary disease; eos = blood eosinophil count in cells per microliter; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroid; LABA = long-acting beta₂-agonist; LAMA = long-acting muscarinic antagonist; mMRC = modified Medical Research Council Questionnaire.

Reference

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD 2022 report. <https://goldcopd.org/2022-gold-reports/>. Accessed March 17, 2022.

Important Information for Health Care Providers receiving this Presentation

- This information is being provided, as a professional courtesy, in response to your request.
- This presentation is for use by the recipient institution or organization, its employees or agents, for medical education purposes only, and should not be edited or forwarded to other third parties.
- You are not speaking on behalf of AstraZeneca and receipt of this presentation does not imply that you are.
- This presentation should not be used for patient education.
- The attached presentation may contain copyright protected work(s).
 - AstraZeneca has obtained permission from the copyright owner to use such work in this presentation
 - You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.